Mantle cell lymphoma

City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
четверг, мая 23, 2024
Research, Hospitals, Clinical Trials, Telemedicine, Virtual Medicine, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, HLA, Ageing, Blood, Transplant, Medicine, NMDP, Survival, Mantle cell lymphoma, Telephone, Constipation, Lymphoma, Neoplasm, Graft-versus-host disease, Happiness, B cell, Physician, Subduction, Pathology, Anemia, Education, Social work, Clinical trial, Hospital, Comfort, Patient, Student, ASCO, GVHD, Occupational therapy, Environment, City, Haematopoietic system, National Marrow Donor Program, Progression-free survival, Bone marrow, TeleVideo, Fatigue, Abstract, Pharmacy, Quality of life, Nursing

City of Hope has performed over 19,000 transplants, is one of the nation’s leading transplant programs and is at the forefront of using transplants to treat older adults with blood cancers.

Key Points: 
  • City of Hope has performed over 19,000 transplants, is one of the nation’s leading transplant programs and is at the forefront of using transplants to treat older adults with blood cancers.
  • The adult cohorts of this trial recruitment have closed with more than 200 patients in follow-up.
  • Kennedy Geriatric Oncology Award, which honors geriatric oncologists who have demonstrated outstanding leadership and achievement in the field of geriatric oncology.
  • Presenter: Richard T. Lee , M.D., City of Hope clinical professor, Supportive and Integrative Medicine Program; Cherng Family Director's Chair for the Center for Integrative Oncology
    Presenter: Daniel Schmolze , M.D., City of Hope associate clinical professor, Department of Pathology

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
вторник, мая 14, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Mantle cell lymphoma, Holocene, Renal cell carcinoma, MCL, FDA, Safety, Protocol, Cancer, NHL, Research and development, Administration, Bone marrow, Lupus nephritis, Pharmaceutical industry

The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.

Key Points: 
  • The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.
  • Preliminary data from the study are anticipated during the fourth quarter of 2024 or first quarter of 2025, depending on patient enrollment and study site activation.
  • Based on ADI-270’s promising profile in preclinical studies to date, Adicet expects to submit an IND for ADI-270 in renal cell carcinoma in the second quarter of 2024.
  • Financial Results for First Quarter 2024:
    Research and Development (R&D) Expenses: R&D expenses were $23.9 million for the three months ended March 31, 2024, compared to $26.8 million during the same period in 2023.

Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

Retrieved on: 
вторник, мая 14, 2024
B cell, Patient, Verismo, Follicular lymphoma, Food, MCL, NK, CD19, FDA, B-cell lymphoma, Therapy, Trial of the century, Malignancy, Safety, Mantle cell lymphoma, Bone marrow, NHL, DLBCL, Pharmaceutical industry

PHILADELPHIA, May 14, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.

Key Points: 
  • Commercially approved CAR T cell therapies have shown impressive high initial response rates in blood cancers.
  • There are currently very limited treatment options for patients with r/r DLBCL who relapse following treatment with commercial CAR T cell therapies.
  • "Verismo Therapeutics is uniquely positioned with SynKIR™-310 to address the significant challenges in treating relapsed/refractory B-cell NHL.
  • This includes cases where patients have relapsed after receiving approved CAR T therapies," stated Dr. Laura Johnson, Chief Scientific Officer of Verismo Therapeutics.

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
четверг, мая 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
среда, апреля 10, 2024
Mantle cell lymphoma, MCL, FDA, Cancer, Inflammation, DLBCL, Paclitaxel, Gilead Sciences, Research, PCNSL, Partnership, B-cell lymphoma, Trial of the century, STAT6, IND, CNS, Lymphoma, Patient, Rheumatoid arthritis, NHL, Chronic lymphocytic leukemia, Central nervous system, AACR, Neoplasm, Clinical trial, Annual general meeting, Therapy, Sanofi, Lymphoid leukemia, Non-Hodgkin lymphoma, Calendar, SAN, BTK, Pharmaceutical industry

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
  • Nurix and Sanofi extended their ongoing research program for STAT6 (signal transducer and activator of transcription 6).
  • Nurix retains its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option.
  • Nurix presented new clinical data for NX-5948 at the American Association for Cancer Research (AACR) 2024 Annual Meeting.

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

Retrieved on: 
среда, апреля 10, 2024
FDA, Lung cancer, AIDX, AI, Radiology, Partnership, Intelligence, Artificial intelligence in healthcare, Lantern, NHL, MCL, A.I, News, Machine learning, Software, TSX, Robotics, Generative, DHL, Patient, Ventricular fibrillation, Safety, Heart, Blockchain, Artificial intelligence, Freedom, Data science, Treatment, Medicine, GLM, Life expectancy, Health, Organization, SAP, USD, Mantle cell lymphoma, OTCQX, OTCQB, Sarcoma, Health care, PALM, Synthetic media, Language, Annual general meeting, Growth, Medical device

PALM BEACH, Fla., April 10, 2024 /PRNewswire/ -- With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and longer lives. Artificial Intelligence (A.I.) has a great demand in the healthcare industry. Healthcare providers turn to tech companies for expertise in adopting AI, and naturally, demand for such expertise makes competition among the latter highly intensive.  A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029.   The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance. Here are some insights about AI and the healthcare market: North America controls the market and has a strong presence of key players; Using AI-powered medical imaging technologies is a huge trend among healthtech companies; Medical businesses continue to grow and expand, so mergers and acquisitions are becoming very common. Larger players are acquiring smaller companies to enhance their AI capabilities or extend their market coverage; The integration of AI with complementary technologies like robotics or blockchain promotes precision medicine and transforms healthcare delivery; and Generative AI-powered virtual assistants and chatbots are experiencing rising requests due to their 24/7 support opportunities."  Active tech companies in the markets this week include Treatment AI, Inc. (OTCQB: TREIF) (CSE: TRUE), Medtronic (NYSE:MDT), NVIDIA (NASDAQ: NVDA), HEALWELL AI Inc. (OTCQX: HWAIF) (TSX: AIDX), Lantern Pharma Inc. (NASDAQ: LTRN).

Key Points: 
  • A report from binariks.com projected that the global artificial intelligence in the healthcare market was valued at USD 16.3 billion in 2022 and is expected to grow at a CAGR of 40.2% to reach USD 173.55 billion by 2029.
  • The report said: "The healthcare AI market is experiencing a remarkable and significant surge in its growth and acceptance.
  • Based on components, the global AI in the healthcare market can be divided into software, hardware, and services.
  • The software segment has the largest share and is expected to have the fastest growth."